Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy

Neuromuscular Disorders

Volumn 22, Issue SUPPL. 3, 2012, Pages

  Marzorati, Mauro ^a   Porcelli, Simone ^a,b   Bellistri, Giuseppe ^a   Morandi, Lucia ^c   Grassi, Bruno ^b  

^a CNR   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Cardiac output; Glycogen storage disease type II; Near infrared spectroscopy; Oxidative metabolism

Indexed keywords

ADULT; ARTICLE; BICYCLE ERGOMETER; CASE REPORT; ENZYME REPLACEMENT; EXERCISE TEST; EXHAUSTION; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; HEART OUTPUT; HEART RATE; HUMAN; IMPEDANCE CARDIOGRAPHY; MALE; NEAR INFRARED SPECTROSCOPY; OXYGEN CONSUMPTION; OXYGENATION; PRIORITY JOURNAL; SKELETAL MUSCLE; VASTUS LATERALIS MUSCLE; WORKLOAD;

ADULT; AGE OF ONSET; ALPHA-GLUCOSIDASES; CARDIAC OUTPUT; ENZYME REPLACEMENT THERAPY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; GLYCOGEN STORAGE DISEASE TYPE II; HEART RATE; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; TREATMENT OUTCOME;

EID: 84870042338     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.10.017     Document Type: Article

References (15)

1. van der Ploeg A.T., Reuser A.J. Pompe's disease. Lancet 2008, 372:1342-1353.
2. Terzis G., Dimopoulos F., Papadimas G.K., et al. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab 2012, 104:279-283.
3. Slonim A.E., Bulone L., Goldberg T., et al. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 2007, 35:70-77.
4. Van den Hout J.M., Reuser A.J., Vulto A.G., Loonen M.C., Cromme-Dijkhuis A., Van der Ploeg A.T. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000, 356:397-398.
5. Kishnani P.S., Corzo D., Nicolino M., et al. Recombinant human acid [alpha]-glucodisase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
6. Case L.E., Koeberl D.D., Young S.P., et al. Improvement with ongoing enzyme replacement therapy in advanced late-onset Pompe disease: a case study. Mol Genet Metab 2008, 95:233-235.
7. Bembi B., Pisa F.E., Confalonieri M., et al. Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 2010, 33:727-735.
8. Strothotte S., Strigi-Pill N., Grunert B., et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 2010, 257:91-97.
9. van der Ploeg A.T., Clemens P.R., Corzo D., et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010, 362:1396-1406.
10. Wokke J.H.J., Escolar D.M., Pestronik A., et al. Clinical features of late-onset Pompe disease: a prospective color study. Muscle Nerve 2008, 38:1236-1245.
11. Richard R., Lonsdorfer-Wolf E., Charloux A., et al. Non-invasive cardiac output evaluation during a maximal progressive exercise test, using a new impedance cardiograph device. Eur J Appl Physiol 2001, 85:202-207.
12. Grassi B., Marzorati M., Lanfranconi F., et al. Impaired oxygen extraction in metabolic myopathies: detection and quantification by near-infrared spectroscopy. Muscle Nerve 2007, 35:510-520.
13. Ferrari M., Mottola L., Quaresima V. Principles, techniques, and limitations of near-infrared spectroscopy. Can J Appl Physiol 2004, 29:463-487.
14. Poole D.C., Hirai D.M., Copp S.W., Musch T.I. Muscle oxygen transport and utilization in heart failure: implications for exercise (in)tolerance. Am J Physiol Heart Circ Physiol 2012, 302:H1050-H1063.
15. Raben N., Wong A., Ralston E., Myerowitz R. Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C 2012, 160C:13-21.